



## King's Research Portal

DOI:

[10.1186/s13195-020-00606-5](https://doi.org/10.1186/s13195-020-00606-5)

*Document Version*

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Newby, D., Prieto-Alhambra, D., Duarte-Salles, T., Ansell, D., Pedersen, L., Van Der Lei, J., ... Nevado-Holgado, A. J. (2020). Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: A multi-national multi-database case-control study. *Alzheimer's Research and Therapy*, 12(1), [38].  
<https://doi.org/10.1186/s13195-020-00606-5>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH

Open Access



# Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study

Danielle Newby<sup>1\*</sup>, Daniel Prieto-Alhambra<sup>3,4</sup>, Talita Duarte-Salles<sup>4</sup>, David Ansell<sup>5</sup>, Lars Pedersen<sup>6</sup>, Johan van der Lei<sup>7</sup>, Mees Mosseveld<sup>7</sup>, Peter Rijnbeek<sup>7</sup>, Glen James<sup>8</sup>, Myriam Alexander<sup>8</sup>, Peter Egger<sup>8</sup>, Jana Podhorna<sup>9</sup>, Robert Stewart<sup>10,11</sup>, Gayan Perera<sup>10</sup>, Paul Avillach<sup>2,7</sup>, Solène Grosdidier<sup>7</sup>, Simon Lovestone<sup>1,12</sup> and Alejo J. Nevado-Holgado<sup>1</sup>

## Abstract

**Background:** Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk.

**Methods:** A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia.

**Results:** Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52–0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95% CI 0.17–0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57–1.37).

**Conclusions:** Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.

**Keywords:** Dementia, Rheumatoid arthritis, Inflammation, Anti-inflammatory drugs, DMARDs, Methotrexate, Sulfasalazine, Case-control study, European Medical Information Framework, EMIF

## Background

Dementia is one of the largest unmet medical needs, and with growing numbers of older people in a majority of countries worldwide, it is set to become an increasing burden on health services and economies [1]. Despite considerable progress in the understanding of the pathological lesions associated with the diseases causing the

commonest forms of dementia—Alzheimer's disease (AD), vascular dementia, dementia with Lewy bodies and fronto-temporal dementia—this has not resulted in therapeutic progress, with multiple trials of compounds designed for disease modification failing, often at a great cost [2]. Whilst part of the failure of such trials might be that they have largely been conducted in patients with established disease, possibly too late for therapeutic benefit, there is an increasing realisation that it is likely forms of dementia are part of a complex set of pathological processes [3]. Understanding these causal pathways, and in particular, understanding their timing in

\* Correspondence: [danielle.newby@psych.ox.ac.uk](mailto:danielle.newby@psych.ox.ac.uk)

<sup>1</sup>Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

relation to the onset of dementia, has become a pressing task in order to progress a novel approach to therapeutic development.

One of the processes that has come under intensive investigation in recent years has been that of inflammation [4–6]. In the analysis of large-scale genome-wide association studies, inflammatory pathways such as complement signalling were consistently identified as altering susceptibility to disease [7, 8]. Post-mortem studies reflect this association with inflammation, as microglial and astrocyte numbers are increased and associated with pathological lesions in disease [9]. However, such genetic and pathological studies are unable to distinguish between cause and effect, and it might be that an inflammatory reaction is part of the defence mechanism or is contributing to disease progression [10].

An alternative approach to understanding the direction and timing of the effect of inflammation in relation to dementia is to utilise existing observational clinical data where individuals have received anti-inflammatory drugs. It was such an approach that first highlighted the role of inflammation in neurodegeneration when it became apparent that non-steroidal anti-inflammatory compounds were associated with reduced dementia risk [11–14].

Many subsequent studies have reproduced this finding, although trials of such compounds have not been successful to date, perhaps because the association is only seen in those taking medication for extended periods of time before the onset of dementia [15]. In line with this, we recently found non-steroidal anti-inflammatory drugs (NSAIDs) were associated with higher cognitive function in participants in the UK Biobank cohort study of largely healthy individuals [16]. Rather than being cognitive enhancers, a potential explanation of this finding is that NSAIDs are reducing the decline in cognitive function in pre-clinical dementia states. Together, these real-world observational clinical data studies, therefore, have made a significant contribution in the following: first, adding support to the association with inflammation in disease; second, in adding support suggesting a direction of that effect; and third, in providing evidence for timing in relation to disease and therefore informing the design of clinical studies.

In recent years, more specific anti-inflammatory drugs have become part of the pharmacotherapy of disorders such as rheumatoid arthritis, providing an opportunity to begin to explore the effects of different mechanisms of inflammation in relation to neurodegeneration [17, 18]. Recognising this, we recently used Clinical Practice Research Datalink (CPRD), a large dataset derived from primary care in the UK, to explore the relationship between different anti-inflammatory compounds and

showed that disease-modifying antirheumatic drugs (DMARDs), and especially methotrexate, are associated with a reduction in risk of incident AD [19]. However, although a relatively large study, the data was from a single source and in a single health care context and thus vulnerable to unanticipated confounding. Here, we set out to replicate and extend this study across multiple real-world observational datasets across Europe.

## Methods

### Study design, setting and source of data

We used a nested retrospective case-control study design to investigate the association between the use of disease-modifying antirheumatic drugs (methotrexate and sulfasalazine) and the incidence of dementia diagnosis in routine healthcare data. We used electronic health records (EHRs) available via the European Medical Information Framework (EMIF; [www.emif.eu](http://www.emif.eu)), a public-private partnership under the EU Innovative Medicines Initiative [20]. Methotrexate and sulfasalazine were selected as follows: (1) both drugs are first-line treatments for rheumatoid arthritis, (2) there is no universally accepted prescribing preference for these drugs when clinicians are faced with the same symptoms and (3) each drug has a different mechanism of anti-inflammatory action [21, 22].

We selected the four databases with primary care, hospital and pharmacy dispensing data sources from across Europe including Integrated Primary Care Information (IPCI, 1.8 million) [23], Aarhus University Prescription Database (AUH, 1.8 million) [24], The Health Information Network (THIN, 3.8 million) [25, 26] and Information System for Research in Primary Care (SIDAP, 5.5 million) [27, 28]. Data collection in IPCI, AUH, THIN and SIDAP was initiated in 1995, 2000, 2002 and 2006, respectively. Data collection for this study was from the first initiation of each database to 2016. Further information regarding the databases utilised is provided in the supplementary information (Table S1).

### Participants and study size

The case population is formed by those individuals who were identified with a first-ever clinical or referral record of dementia. Further information regarding dementia definitions and mapping to the different databases in this study can be found in Perera et al. [29]. The clinical codes for dementia and other disease variables can be found in the supporting information (Table S2).


The date at which a patient received the first diagnosis of dementia was defined as the index date. Up to 25 controls from the initial study population per case were matched on age ( $\pm 2$  years), gender and GP practice. Up to 25 controls were utilised as it was anticipated that when only including those people with a previous

history of RA for analysis, the number of controls would decrease. For the AUH database, information on GP practice was not available; therefore, controls were matched to cases on age and gender only. All individuals included in the analysis had been registered in their respective database for at least 1 year before the index date. The index date for controls (with no dementia diagnosis at their index date or before) was chosen as the date of dementia diagnosis of their matched dementia case. From this initial population of cases and controls, only those people who were 50 years or older at the index date were included in the study. Furthermore, for each case, matched controls who had a shorter period before the index date were removed. Finally, only those people with a diagnosis of rheumatoid arthritis (RA) before the index date were included in this study. Any cases with no remaining controls after applying exclusion criteria were excluded. A population flow-chart showing the individual numbers of cases and controls per dataset is shown in Fig. 1.

**Outcome and exposures**

The outcome variable was defined as the presence or absence of a diagnosis of dementia as a binary variable. The diagnosis of dementia was identified in each

database as a first-ever clinical or referral record of dementia from 1 January 1995 to 31 December 2016. The diagnosis of rheumatoid arthritis was identified in each database as a first-ever clinical or referral record of rheumatoid arthritis. The exposure variables in this study were as follows: first prescription of methotrexate, if any; first prescription of sulfasalazine, if any; number of days using methotrexate before index date; and number of days using sulfasalazine before the index date. The number of days of drug use was calculated from the first date of drug use to the last date of drug use followed by a 12-month gap all before the index date. Days of use for these drugs were converted to years by dividing by 365.25 for consistency. In order to standardise drug treatments across the different databases if information on dosing is available, the duration was calculated by dividing the amount of drug prescribed and the actual dosing of the individual patient. If information on dosing was lacking or in case of missing dose, the total amount (per prescription) is divided by the recommended dosing according to the Summary of Product Characteristics (SmPC)/defined daily dose of the respective drug. ATC drug codes for the two anti-inflammatory medications were L01BA01 and L04AX03 for methotrexate and A07EC01 for sulfasalazine. All databases utilised ATC



codes for methotrexate and sulfasalazine apart from THIN, which utilises ATC and Read coding.

#### Potential confounders and model adjustments

Factors considered potential confounders were identified including age at index date, highest body mass index measurement (BMI) 2–12 years before the index date (either BMI or calculated from height and weight measurements) and comorbidities at or before the index date (stroke and acute myocardial infarction (AMI)). Age was included as a confounder in all models due to the 2-year time window used for matching. The highest BMI 2–12 years from the index date was used when available, but calculated from weight and highest height recorded in adulthood otherwise. The highest BMI was utilised as dementia patients are more likely to lose weight leading up to diagnosis [30]. Any BMI value less than 15 kg/m<sup>2</sup> or greater than 60 kg/m<sup>2</sup>, any weight measurement less than 30 kg or greater than 150 kg and any height measurement less than 1 m or greater than 2.5 m were considered measurement errors and not considered. Cardiovascular disease, including stroke, has been hypothesised as lying on the causal pathway between RA and dementia, where people with RA are more at risk of developing cardiovascular disease such as stroke, which is then a risk factor for dementia [31, 32]; therefore, models were used with and without this previous history of stroke.

We initially performed an unadjusted model and then we adjusted for age at the index date (years), diagnosis of stroke before the index date (yes or no), diagnosis of

AMI (yes or no) and BMI, and finally, fully adjusted models with all confounders but without the previous stroke diagnosis were performed.

#### Missing data

The only confounding variable with missing data was the highest BMI (2–12 years) with missingness of 39.57%. BMI was imputed to avoid the exclusion of patients and to reduce selection bias. An imputed dataset was generated using 10 multiple imputations by chained equations to replace these missing values. We included all confounders, diagnosis of hypertension, dementia diagnosis and both drug exposures in the imputation process.

#### Statistical methods

A descriptive summary table of the dataset utilised is presented in Table 1. For the descriptive summary statistics used in this study, an unpaired *t* test was applied for normally distributed numerical demographics, a Wilcoxon unpaired *t* test was applied for non-normally distributed numerical demographics and a chi-square test for categorical demographics was applied.

Conditional logistic regression was used to estimate the association between drug use and dementia diagnosis using R version 3.4.3 and the “survival” package [33]. The data from each database was combined into one dataset, and a variable indicating which database the data had originated from was created. We first calculated the odds ratios (ORs) with 95% confidence intervals (CI) from crude models with no adjustment (model

**Table 1** Characteristics of cases and controls (with and without dementia) with rheumatoid arthritis used in this study

	Case (with dementia diagnosis)	Control (no dementia diagnosis)	<i>p</i> value
<i>n</i>	486	641	–
Age at index date (years)	79.8 (± 6.89)	79.5 (± 7.02)	0.522
Gender	86.4% F	87.4% F	0.707
Time since rheumatoid arthritis diagnosis before the index date (years)	6.87 (± 6.29)	7.06 (± 5.92)	0.232
Prescribed with sulfasalazine	40 (8.23%)	57 (8.89%)	0.776
Years of sulfasalazine use before the index date	2.72 (± 3.57)	2.57 (± 3.96)	0.457
Prescribed with methotrexate	123 (25.3%)	178 (27.77%)	0.392
Years of methotrexate use before the index date	2.69 (± 3.06)	3.80 (± 2.44)	0.002
Prescribed with methotrexate or sulfasalazine	19 (3.91%)	25 (3.90%)	1.000
Diagnosed with AMI	26 (5.35%)	34 (5.30%)	1.000
Diagnosed with stroke	37 (7.60%)	64 (10.00%)	0.202
Highest BMI before the index date	28.1 (± 4.99)	28.8 (± 4.90)	0.061
BMI missingness	178 (36.62%)	211 (32.92%)	0.217
Total time in database (years)	7.64 (± 7.82)	7.77 (± 7.66)	0.301
Time in database before the index date (years)	5.16 (± 7.47)	4.62 (± 7.01)	0.027

Case, diagnosis of dementia; control, no diagnosis of dementia. For the calculation of *p* values to compare the demographics between cases and controls, an unpaired *t* test was applied for normally distributed numerical demographics, a Wilcoxon unpaired *t* test was applied for non-normally distributed numerical demographics and a chi-square test for categorical demographics was applied

0). Secondly, we adjusted for all confounders listed in the “[Potential confounders and model adjustments](#)” section: age at index date (years), diagnosis of stroke before the index date (yes or no), diagnosis of AMI (yes or no) (model 1) and database (multi-level variable). Finally, we calculated the models with all confounders but without the previous stroke diagnosis (model 2).

To test the impact of days of use of anti-inflammatory medications before dementia diagnosis, a new variable was created based on the days of use of either methotrexate or sulfasalazine. For each medication, days of use before the index date were converted into tertiles for those taking medication. This created a multi-level variable of the different tertiles based on the days of use of the medication. Those not taking the medication were as the reference level in the analysis. The four groups created for methotrexate days of use variable were as follows: group A (reference level  $n = 740$ ), not taking methotrexate; group B ( $n = 52$ ), more than 0 years but less than or equal to 1.18 years (432.33 days) of methotrexate use before the index date; group C ( $n = 51$ ), those with greater than 1.18 years but less than or equal to 4.11 years (1500.8 days) of use of methotrexate before the index date; and finally, group D ( $n = 51$ ), those taking methotrexate for more than 4.11 years. The four groups created for sulfasalazine days of use variable were as follows: group A (reference level), not taking sulfasalazine; group B, more than 0 days but less than or equal to 0.49 years (177.5 days) of sulfasalazine use before the index date; group C, those with greater than 0.49 years but less than or equal to 2.21 years (808 days) of use of sulfasalazine before the index date; and finally, group D, those taking sulfasalazine for more than 2.21 years. This multi-level variable, containing the different tertiles based on days of use for either methotrexate or sulfasalazine, was then included into the models (instead of the binary variable indicated if the drug was taken by the patient), and models 0–2 were calculated using this multi-level variable.

## Results

### Descriptive data

A total of 486 subjects with RA who developed dementia (cases) and 641 matched controls also with RA were included. A study participant flowchart is provided showing the impact of each exclusion criterion (Fig. 1). Characteristics of individuals included in the study are shown in Table 1. IPCI had 433 patients (37% cases), SIDIAP 454 (47% cases), THIN 153 (47% cases) and AUH 87 (48% cases).

Cases and controls were balanced in terms of most of the measured variables (Table 1). Additionally, although the total time in the database between cases and controls did not differ, controls had slightly shorter time in the

databases compared with the cases with time in the database before the index date at 5.16 years for cases and 4.62 years for controls. However, this difference is not present in three databases (AUH, SIDIAP and THIN) when considering the individual databases. The difference is due to the IPCI dataset having more cases with a higher number of controls who have a shorter time before the index date. Other covariates did not differ between cases and controls to a statistically significant extent. The total range of ages at the index date for cases and controls in Table 1 was 50–97 years and 52–97 years, respectively. The total range of methotrexate use in years was 0.074–18.8 years, and the total range of sulfasalazine use in years was 0.036–19.5 years. For a detailed breakdown of the duration of methotrexate and sulfasalazine use across 5-year age brackets for dementia cases, see the supporting information (Table S3).

### Association between DMARDs use and dementia diagnosis

For the unadjusted model, there was a trend, although not statistically significant, towards reduced risk of dementia with methotrexate use (OR 0.76, 95% CI 0.56–1.03). Using adjusted models, we found a statistically significant association with methotrexate but no association with sulfasalazine in relation to dementia diagnosis. For models 1 and 2, similar ORs were obtained for methotrexate (0.71, 95% CI 0.52–0.98; 0.71, 95% CI 0.52–0.98) both achieving statistical significance (Table 2). As models 1 and 2 show similar results, we conclude that there is no significant effect of stroke on the relationship between drug exposure and dementia onset. A forest plot showing the results of Table 2 can be found in the supplementary information (Figure S1).

We then investigated the number of days of use of methotrexate and sulfasalazine before dementia diagnosis. The results showing the number of days of use of methotrexate in tertiles with dementia diagnosis are shown in Fig. 2.

We found a clear treatment time effect (even though tertiles 1 and 2 were not significant) with those taking methotrexate for the longest period (greater than 4.11 years) prior to the index date having the greatest effect on dementia risk for all models (Fig. 2). The results indicate that the association is only significant for those who took methotrexate for a minimum of over 4 years of treatment. For the unadjusted model, those who took methotrexate for a minimum of 4.11 years achieved an odds ratio of 0.39 (95% CI 0.18–0.84,  $p$  value 0.015) with similar odds ratios obtained for models 1 and 2 of 0.38 (95% CI 0.18–0.84,  $p$  value 0.016) and 0.37 (95% CI 0.17–0.79,  $p$  value 0.011), respectively.

The full table of results can be found in the supplementary information (Table S4). We then repeated this

**Table 2** Unadjusted and adjusted model showing the association between methotrexate and sulfasalazine treatment and dementia diagnosis in people with rheumatoid arthritis using conditional logistic regression

Drug	Model 0		Model 1		Model 2	
	Unadjusted OR (95% CI)	p value	Adjusted OR (95% CI)	p value	Adjusted OR (95% CI)	p value
Methotrexate	0.76 (0.56–1.03)	0.076	0.72 (0.52–0.98)	0.036	0.71 (0.52–0.98)	0.034
Sulfasalazine	0.88 (0.57–1.36)	0.56	0.89 (0.57–1.38)	0.60	0.88 (0.57–1.37)	0.57

Model 0, no adjustment; model 1, adjustment for age, BMI, stroke and AMI; model 2, same as model 1 but not including diagnosis of stroke. OR odds ratio for dementia risk

analysis for sulfasalazine finding no significant association between duration of prescription and risk of dementia (Table 3). However, it is interesting to note that the general trend (even though all values are not significant) indicating longer use is associated with increased dementia risk.


**Discussion**

In this uniquely large and geographically diverse sample using four European harmonised electronic health record datasets using the EMIF platform, we found evidence that in adults older than 50 years of age with rheumatoid arthritis, taking methotrexate was associated with a lower risk of a subsequent dementia diagnosis, specifically recorded methotrexate use for more than 4 years. We also investigated sulfasalazine use but found no such association.

However, the lack of association between sulfasalazine and dementia could also be attributed to the low frequency of sulfasalazine usage in these databases, and this

could provide an account for the lack of statistically significant reduction in dementia risk.

The data used in this study does not permit any conclusive causal information regarding the biological mechanisms of the anti-inflammatory properties of methotrexate relative to sulfasalazine in relation to dementia risk. However, by identifying the potential mechanisms and how they differ between the two drugs will be helpful in pointing to future directions for understanding the underlying mechanisms in basic research of inflammation and dementia, which would need to be understood before any such compounds would be tested in intervention trials. The exact mechanism of action of methotrexate or sulfasalazine is not well understood; however, several overlapping and distinct mechanisms have been proposed. For methotrexate, these mechanisms include folate-dependent processes, adenosine signalling, inhibition of methyl-donor production, generation of reactive oxygen species, alteration of cytokine profiles and downregulation of adhesion molecule



**Table 3** Unadjusted and adjusted model showing the association between days of use of sulfasalazine treatment and dementia diagnosis in people with rheumatoid arthritis using conditional logistic regression

Variable group	Model 0		Model 1		Model 2	
	Unadjusted OR (95% CI)	<i>p</i> value	Adjusted OR (95% CI)	<i>p</i> value	Adjusted OR (95% CI)	<i>p</i> value
No sulfasalazine use	Ref		Ref		Ref	
Sulfasalazine use for 0.49 years (first tertile)	0.60 (0.28–1.31)	0.20	0.65 (0.30–1.41)	0.28	0.65 (0.30–1.41)	0.28
Sulfasalazine use for 0.49 to 2.21 years (second tertile)	0.93 (0.45–1.93)	0.85	0.94 (0.45–1.95)	0.86	0.89 (0.43–1.85)	0.76
Sulfasalazine use for > 2.21 years (third tertile)	1.21 (0.58–2.51)	0.62	1.16 (0.55–2.44)	0.69	1.19 (0.57–2.48)	0.65

Model 0, no adjustment; model 1, adjustment for age, BMI, stroke and AMI; model 2, same as model 1 but not including stroke variable. OR odds ratio for dementia risk

expression, eicosanoids and matrix metalloproteinases [34]. For sulfasalazine, it is still not clear whether the parent drug and/or its main metabolites (sulfapyridine and mesalazine) are responsible for the beneficial effects in rheumatoid arthritis [35, 36]. Based on in vitro and in vivo studies, sulfasalazine appears to exert effects on inflammatory cell function, cytokine and antibody production, inhibition of folate-dependent enzymes, inhibition of synovial neovascularization and free radical scavenging activity [37]. Both methotrexate and sulfasalazine appear to be involved in adenosine signalling [38–40] and affect T cell activity via CD8 and inhibit B cells by interrupting Ig synthesis whereas only methotrexate interferes with IL-2, and only sulfasalazine causes prostaglandin inhibition. There is evidence in the literature that methotrexate is involved in the inhibition of inflammatory cell proliferation, interference with T cell activity and cytokine secretion, and augmented release of adenosine, macrophage and polymorphonuclear leukocyte inhibition where this has not been shown with sulfasalazine [37, 38]. These drugs are involved in overlapping and distinct mechanisms, and this could potentially explain why we did not see an association between sulfasalazine and dementia risk. However, the lack of cumulative measures reflecting inflammatory disease burden precludes definitive conclusions regarding the causal relationship between methotrexate use, reduced inflammation and lowered risk of dementia.

Investigations of anti-inflammatory DMARDs on dementia risk have reported conflicting results. Judge et al. [19] showed a decreased risk of dementia with methotrexate use. Using the UK Clinical Practice Research Datalink, Judge et al. found that DMARD users were at reduced risk of dementia (hazard ratio 0.60; 95% confidence interval 0.42–0.85), and the effect was strongest in methotrexate users (hazard ratio 0.52; 95% confidence interval 0.34–0.82). Our study extends these findings by utilising datasets across multiple countries as well as highlighting the stronger associations of longer methotrexate use with reduced dementia risk.

Judge et al. contradict the study carried out by Chou et al. [41]. In this study, using the Taiwan National Health Insurance Research Database, people taking non-biologic DMARDs had a higher risk of any dementia type (AD, vascular) compared with people who did not take DMARDs or used biologic DMARDs. This study used a cut-off age of people equal or older than 20 years; however, the majority of people used in the analysis were older than 65 (> 80%). Furthermore, this study also showed that the numbers of days of use of either methotrexate or sulfasalazine increased dementia risk. The contradictory results from this study could be for a number of reasons, firstly differences in geographic locations (European versus Asian). Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as dementia risk with the use of other DMARDs, particularly biological therapies. Future experimental studies are warranted to determine the specific mechanisms for the protective association between prior methotrexate treatment and dementia.

Our study has several strengths. First, the use of multiple routine EHR databases under the EMIF platform has allowed for aggregation and harmonisation of huge volumes of suitable data to investigate the association between dementia and inflammatory exposures. The access to large amounts of data has meant that we have been able to select people with a relatively rare condition such as RA and have sufficient numbers of incident cases of dementia. By only including people who had RA in this study, we have increased the likelihood of cases and controls being comparable rather than just comparing medication use or not within the total samples and therefore could consider the effect of medications and dementia risk. In this study, we used a matched population, which minimises bias due to confounding by indication but also limits the generalizability of the findings. In particular, we only utilised those people with RA also limiting our generalizability. In this study, four EHR



databases, primary care and hospital-based, from four European countries, were utilised, giving general applicability across multiple European countries. Second, we followed an EMIF harmonisation process where a single protocol was utilised for the study, single format of data extracts, semantic harmonisation process ensuring comparability of clinical code lists and a statistical analysis plan with the same statistical analysis steps applied on the extracted data ensuring consistency in results.

Our study also had limitations. We only investigated the effect of two anti-inflammatory drugs, methotrexate and sulfasalazine, without considering the impact of other drug treatments potentially administered such as biologics and concomitant use of biologics and other non-biologic anti-inflammatory medications. Therefore, confounding by indication could exist as the severity of RA may impact the choice of medication where methotrexate and sulfasalazine are usually the first-line treatments for RA. Therefore, the characteristics of patients receiving methotrexate versus sulfasalazine could be different due to the underlying disease severity (as measured by the Disease Activity Score 28 (DAS28), presence/absence of joint erosions and other inflammatory biomarkers) and degree of inflammation and therefore could contribute to confounding by indication. However, Judge et al. [19] used propensity score matching to account for confounding by indication and showed similar results to ours regarding a reduced risk of dementia with methotrexate use. Furthermore, drug adherence could affect the results with drug side effects which could affect the compliance of taking the medications utilised in this study. Additionally, discontinuation of drug treatment could impact the degree of undefined inflammation leading up the onset of dementia in cases. Based on the study design, it is feasible that some patients had continuous treatment and others did not. Additionally, cases and controls who used both methotrexate and sulfasalazine were included in the analysis, adding another potential confounder that weakens the overall statistical association between methotrexate use and lowered risk of dementia. Owing to the observational nature of the study, there remains the potential for residual confounding that could attenuate or explain the observed associations, due to unmeasured variables such as arthritis disease severity, health, concomitant therapy and lifestyle effects such as physical activity and alcohol consumption. However, in spite of this, the data used for this study does reflect the wider rheumatoid arthritis patient population in terms of gender distribution [42].

Regarding the clinical diagnosis of dementia, there is the possibility of non-uniform case assignment. However, it is reasonable that all countries (the UK, Spain, Denmark and Holland) have dementia assessment

services and the potential for specialist diagnoses (which are more likely to vary in coverage within rather than between sites) and that this will be more likely to have obscured our findings through case heterogeneity and measurement error rather than give rise to false-positive findings. Furthermore, the diagnosis of dementia is usually assessed by a general practitioner and not by a standardised research diagnosis, which may differ depending on the type of dementia, so this may attenuate the associations. We also defined dementia to encompass any type of dementia including Alzheimer's disease and vascular dementia; therefore, it might be possible that a specific subtype of dementia is driving the association.

Further work, from this study, would be to establish the following: firstly, if other anti-inflammatory medications such as hydroxychloroquine and leflunomide affect dementia risk; secondly, whether biological anti-inflammatories reduce dementia risk; thirdly, if these associations are effected by NSAID and prednisone usage; and finally, whether methotrexate treatment affects the risk in the different dementia subtypes.

## Conclusion

In summary, this case-control study across multiple EHR databases found that prior methotrexate use, but not sulfasalazine use, was associated with dementia diagnosis even after adjusting for patients' demographics and comorbidities. Furthermore, we showed that there is a gradual decrease against dementia risk the longer the use of methotrexate before the index date. These findings are relevant from a public health perspective since they highlight the potential of methotrexate to protect against dementia; however, the mechanism behind this remains to be elucidated.

## Supplementary information

**Supplementary information** accompanies this paper at <https://doi.org/10.1186/s13195-020-00606-5>.

**Additional file 1** : Supporting Information.xlsx Description of data: Excel document containing 1). **Table S1.** of characteristics of databases utilised in this study 2). **Table S2.** of clinical diagnosis codes for disease variables 3). **Table S3.** of the age specific breakdown of dementia occurrence in 5 year intervals with duration of drug treatment usage 4). **Table S3.** showing the association between of days of use of methotrexate treatment and dementia diagnosis in people with rheumatoid arthritis and 5). **Figure S1.** showing the association between methotrexate and sulfasalazine treatment with dementia diagnosis in people with rheumatoid arthritis.

## Abbreviations

AD: Alzheimer's disease; MTX: Methotrexate; SUL: Sulfasalazine; DMARDs: Disease-modifying antirheumatic drugs; NSAIDs: Non-steroidal anti-inflammatory drugs; EMIF: European Medical Information Framework; ATC: Anatomical Therapeutic Chemical; THIN: The Health Information Network; AUH: Aarhus University Prescription Database; IPCI: Integrated Primary Care Information; SIDIAP: Information System for Research in Primary Care; ICD-9/10: International Classification of Diseases; ICPC: International

Classification of Primary Care; RA: Rheumatoid arthritis; BMI: Body mass index; AMI: Acute myocardial infarction

### Acknowledgements

The European Medical Information Framework (EMIF) is a collaboration between industry and academic partners that aims to develop common technical and governance solutions to facilitate access to diverse electronic medical and research data sources. These analyses were supported by the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372, resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution. The authors would like to acknowledge Montse Camprubi, Carlos Díaz and Alba Jene for their administrative support and support during submission to the ethical review boards and Laura Winchester for the helpful discussions and comments on the manuscript. Support from this work was received from the NIHR Biomedical Research Centre at Oxford Health NHS Foundation Trust.

### Role of the funding source

The study sponsors had no involvement in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

### Authors' contributions

ANH, SL conceived the idea for this study under the EMIF consortium. DN, ANH designed the study with input from DPA, GJ, MA, PE, JP, RS, GP, PA, SG, SL, MM, PR, JVDL developed the extraction pipeline and tools and provided the analysis platform. TDS, DA, LP, JVDL, carried out the data extraction for each individual dataset. DN carried out all analysis for the study and wrote the manuscript with input from all authors. The author(s) read and approved the final manuscript.

### Funding

FP7 Ideas: European Research Council Award Number 115372. ERC had no role in the design of the study; in the collection, analysis and interpretation of the data; and in the writing of the manuscript. DPA is funded by a National Institute for Health Research Clinician Scientist award (CS-2013-13-012). This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

### Availability of data and materials

The datasets analysed during the current study are not publicly available due to the confidentiality of patients but are available via application to individual data custodians under the EMIF platform (<http://www.emif.eu/>).

### Ethics approval and consent to participate

This study obtained ethical approval from each one of the databases utilised.

### Consent for publication

All authors have reviewed and approved the manuscript.

### Competing interests

SL is currently an employee of Janssen-Cilag'.

### Author details

<sup>1</sup>Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK. <sup>2</sup>Department of Biomedical Informatics, Harvard Medical School, Boston, USA. <sup>3</sup>Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK. <sup>4</sup>Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. <sup>5</sup>Quintile IMS, London, UK. <sup>6</sup>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. <sup>7</sup>Department of Medical Informatics, Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands. <sup>8</sup>Real World Data, GlaxoSmithKline, Uxbridge, UK. <sup>9</sup>Boehringer Ingelheim International GmbH, Medicine CNS & Emerging Areas, Ingelheim am Rhein, Germany. <sup>10</sup>Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK. <sup>11</sup>South London and Maudsley NHS Foundation Trust, London, UK. <sup>12</sup>Janssen-Cilag', Beerse, Belgium.

Received: 27 August 2019 Accepted: 23 March 2020

### References

- Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina AM, Winblad B, et al. The worldwide costs of dementia 2015 and comparisons with 2010. *Alzheimers Dement*. 2017;13:1–7. <https://doi.org/10.1016/j.jalz.2016.07.150>.
- Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. *Alzheimers Res Ther*. 2014;6:37. <https://doi.org/10.1186/alzrt269>.
- Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. *Acta Neuropathol*. 2017;134:171–86. <https://doi.org/10.1007/s00401-017-1717-7>.
- Ransohoff RM. How neuroinflammation contributes to neurodegeneration. *Science*. 2016;353:777–83. <https://doi.org/10.1126/science.aag2590>.
- Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: current evidence and future directions. *Alzheimers Dement*. 2016;12:719–32. <https://doi.org/10.1016/j.jalz.2016.02.010>.
- Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. *Lancet Neurol*. 2015;14:388–405. [https://doi.org/10.1016/S1474-4422\(15\)70016-5](https://doi.org/10.1016/S1474-4422(15)70016-5).
- Yeh FL, Hansen DV, Sheng M. TREM2, microglia, and neurodegenerative diseases. *Trends Mol Med*. 2017;23:512–33. <https://doi.org/10.1016/j.molmed.2017.03.008>.
- Jones L, Holmans PA, Hamshere ML, Harold D, Moskva V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. *PLoS One*. 2010;5:e13950. <https://doi.org/10.1371/journal.pone.0013950>.
- Hopperton KE, Mohammad D, Trépanier MO, Giuliano V, Bazinet RP. Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review. *Mol Psychiatry*. 2018;23:177–98. <https://doi.org/10.1038/mp.2017.246>.
- Newcombe EA, Camats-Perna J, Silva ML, Valmas N, Huat TJ, Medeiros R. Inflammation: the link between comorbidities, genetics, and Alzheimer's disease. *J Neuroinflammation*. 2018;15:276. <https://doi.org/10.1186/s12974-018-1313-3>.
- Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. *Neurology*. 1995;45:1441–5.
- Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. *Neurobiol Aging*. 1995;16:523–30.
- McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. *Neurology*. 1996;47:425–32.
- Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. *Neurology*. 1997;48:626–32.
- in 't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. *N Engl J Med*. 2001;345:1515–21. <https://doi.org/10.1056/NEJMoa010178>.
- Nevado-Holgado AJ, Kim C-H, Winchester L, Gallacher J, Lovestone S. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. *BMJ Open*. 2016;6:e012177. <https://doi.org/10.1136/bmjopen-2016-012177>.
- Wang J, Tan L, Wang H-F, Tan C-C, Meng X-F, Wang C, et al. Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis. *J Alzheimers Dis*. 2015;44:385–96. <https://doi.org/10.3233/JAD-141506>.
- Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*. 2018;9:7204–18. <https://doi.org/10.18632/oncotarget.23208>.
- Judge A, Garriga C, Arden NK, Lovestone S, Prieto-Alhambra D, Cooper C, et al. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. *Alzheimer's Dement Transl Res Clin Interv*. 2017;3:612–21. <https://doi.org/10.1016/j.trci.2017.10.002>.
- Oliveira JL, Trifan A, Bastião Silva LA. EMIF Catalogue: a collaborative platform for sharing and reusing biomedical data. *Int J Med Inform*. 2019; 126:35–45. <https://doi.org/10.1016/j.ijmedinf.2019.02.006>.
- Benjamin O, Bansal P, Goyal A, et al. Disease Modifying Anti-Rheumatic Drugs (DMARD) [Updated 2020 Feb 27]. In: StatPearls [Internet]. Treasure

- Island (FL): StatPearls Publishing; 2020 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK507863/>.
22. Münster T, Furst DE. Pharmacotherapeutic strategies for disease-modifying antirheumatic drug (DMARD) combinations to treat rheumatoid arthritis (RA). *Clin Exp Rheumatol*. 1999;17:529–36.
  23. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. *Methods Inf Med*. 1999;38:339–44.
  24. Grann AF, Erichsen R, Nielsen AG, Frøslev T, Thomsen RW. Existing data sources for clinical epidemiology: the clinical laboratory information system (LABKA) research database at Aarhus University, Denmark. *Clin Epidemiol*. 2011;3:133–8. <https://doi.org/10.2147/CLEP.S17901>.
  25. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. *Inform Prim Care*. 2004;12:171–7.
  26. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. *Pharmacoepidemiol Drug Saf* 2007;16:393–401. doi:<https://doi.org/10.1002/pds.1335>.
  27. García-Gil MDM, Herosilla E, Prieto-Alhambra D, Fina F, Rosell M, Ramos R, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). *Inform Prim Care*. 2011;19:135–45.
  28. Bolibar B, Fina Avilés F, Morros R, del Mar G-GM, Herosilla E, Ramos R, et al. Base de datos SIDIAP: la historia clínica informatizada de Atención Primaria como fuente de información para la investigación epidemiológica. *Med Clin (Barc)*. 2012;138:617–21. <https://doi.org/10.1016/j.medcli.2012.01.020>.
  29. Perera G, Pedersen L, Ansel D, Alexander M, Arrighi HM, Avillach P, et al. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: the European Medical Informatics Framework resource. *Alzheimers Dement*. 2018;14:130–9. <https://doi.org/10.1016/j.jalz.2017.06.2270>.
  30. Stewart R, Masaki K, Xue Q-L, Peila R, Petrovitch H, White LR, et al. A 32-year prospective study of change in body weight and incident dementia. *Arch Neurol*. 2005;62:55. <https://doi.org/10.1001/archneur.62.1.55>.
  31. Semb AG, Kvien TK, Aastveit AH, Jungner I, Pedersen TR, Walldius G, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISK (AMORIS) Study. *Ann Rheum Dis*. 2010;69:1996–2001. <https://doi.org/10.1136/ard.2009.126128>.
  32. Baena-Díez JM, García-Gil M, Comas-Cufí M, Ramos R, Prieto-Alhambra D, Salvador-González B, et al. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. *Heart*. 2018;104:119–26. <https://doi.org/10.1136/heartjnl-2017-311279>.
  33. Terry M, Therneau M. Package “survival” title survival analysis; 2019.
  34. Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. *Nat Rev Rheumatol*. 2016;12:731–42. <https://doi.org/10.1038/nrrheum.2016.175>.
  35. Taggart AJ, Neumann VC, Hill J, Astbury C, Le Gallez P, Dixon JS. 5-Aminosalicylic acid or sulphapyridine: which is the active moiety of sulphasalazine in rheumatoid arthritis? *Drugs*. 1986;32:27–34. <https://doi.org/10.2165/00003495-198600321-00006>.
  36. Bird HA. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid—which is the active moiety in rheumatoid arthritis? *Rheumatol*. 1995;34:16–9. [https://doi.org/10.1093/rheumatology/XXXIV.suppl\\_4.16](https://doi.org/10.1093/rheumatology/XXXIV.suppl_4.16).
  37. Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. 1997;36:382–86. <https://doi.org/10.1093/rheumatology/36.3.382>.
  38. Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. *Jt Bone Spine*. 2019;86:301–7. <https://doi.org/10.1016/j.jbspin.2018.07.004>.
  39. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. *Arthritis Res*. 2002;4:266. <https://doi.org/10.1186/ar419>.
  40. Morabito L, Montesinos MC, Schreiber DM, Balter L, Thompson LF, Resta R, et al. Methotrexate, and adenosine release methotrexate and sulfasalazine promote adenosine release by a mechanism that requires Ecto-5-nucleotidase-mediated conversion of adenosine nucleotides. 1998;101(2):295–300. <https://doi.org/10.1172/JCI1554>.
  41. Chou M-H, Wang J-Y, Lin C-L, Chung W-S. DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: a propensity

- score-matched case-control study. *Toxicol Appl Pharmacol*. 2017;334:217–22. <https://doi.org/10.1016/j.taap.2017.09.014>.
42. Kvien TK, Uhlig T, Ødegård S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: the sex ratio. *Ann N Y Acad Sci*. 2006;1069:212–22. <https://doi.org/10.1196/annals.1351.019>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

